Novel intravaginal ring shows promise for HIV prevention

July 2, 2014

A novel intravaginal ring implanted with anti-retroviral drug tablets, or pods, demonstrated sustained and controlled drug release and safety over 28 days, according to a paper published ahead of print in Antimicrobial Agents and Chemotherapy. The ring, designed to prevent transmission of HIV, was tested in pig-tailed macaque monkeys, and is engineered to be inexpensive, all the better for use in developing countries, says corresponding author Marc Baum.

One of the two tested in the ring had been shown in three clinical trials to prevent HIV—some of the time—when taken orally, and is the only product approved by the US Food and Drug Administration (FDA) for HIV prophylaxis.

The ring's topical drug delivery has critical advantages over oral therapy. People often fail to take their medications as prescribed. That probably accounts for some of the wide variation in risk reduction in the three , which ranged from 44 to 75 percent, says Baum, of the Oak Crest Institute of Science, Pasadena, CA. "Issues such as adherence to a regular dosing schedule are significantly reduced by continuous release of the drugs into the vaginal mucosa independently of coitus and daily dosing."

"The ring maintained steady state drug levels in the vaginal tissues, the key anatomic compartment for preventing sexual HIV transmission, and eliminated the concentration troughs encountered with oral medications," says Baum. "This should boost effectiveness." These tests, in the monkeys, were performed by James M. Smith's group at the Centers for Disease Control and Prevention, Atlanta.

"In addition, systemic levels are so low as to usually be undetectable in topical delivery," says Baum. "That means that side effects are dramatically reduced, or eliminated entirely."

The ring is a simple, unmedicated, impermeable elastomer scaffold on which the investigators implanted polymer-coated drug tablets, each containing a different drug. These deliver the drug directly to the vaginal mucosa, via channels in the elastomer ring, which exposes the pods to vaginal fluids.

An additional requirement for safety and efficacy is that the ring must not trigger immune defenses, and their associated inflammation, as that could encourage HIV infection by compromising the integrity of the mucosal barrier, as well as by recruiting and activating immune cells that are the virus's targets. And in fact, the immune system, and the vaginal microbiome were undisturbed.

Baum notes that the pig-tailed macaque model is an ideal surrogate for humans. "The model has similarities with the human menstrual cycle, vaginal architecture and vaginal microbiome, and the ability to conduct efficacy studies with simian-human immunodeficiency virus," he says.

"Macaques cannot be infected with HIV, so scientists have developed a hybrid virus, simian-human , that infects the monkeys and leads to a disease much like AIDS," Baum explains. This virus contains parts of the , and is susceptible to many HIV drugs, he says. "This is the state of the art for studying HIV/AIDS in vivo."

The two combinations tested include Truvada, which consists of emtricitabine and tenofovir disoproxil fumarate, and Truvada plus maraviroc, which works by blocking the chemokine receptor, CCR5, which is a target entryway of HIV.

Explore further: First dual-protection intravaginal ring design shows promise in long-term HIV and pregnancy prevention

More information: The manuscript can be found online: aac.asm.org/content/early/2014 … 871-14.full.pdf+html . The final version of the article is scheduled for the September 2014 issue of Antimicrobial Agents and Chemotherapy.

Related Stories

First dual-protection intravaginal ring design shows promise in long-term HIV and pregnancy prevention

November 12, 2013
A new intravaginal ring (IVR) has been developed for the sustained 90-day co-delivery of tenofovir and levonorgestrel, an anti-human immunodeficiency virus (HIV) drug and a contraceptive. Tenofovir is the only topical prophylactic ...

Vaginal gel might prevent HIV hours after exposure

March 12, 2014
(HealthDay)—A new vaginal gel has the potential to protect women from HIV, even if it is applied several hours after sex, animal research suggests.

Novel intravaginal ring shows promise in HIV prevention

October 16, 2012
A new 90-day intravaginal ring has been developed—that for the first time—enables the long-lasting vaginal delivery of tenofovir (TFV), the only topical prophylactic shown to be effective at reducing the sexual transmission ...

New medical device extremely effective at preventing HIV in women

September 27, 2013
It's often said that the HIV/AIDS epidemic has a woman's face. The proportion of women infected with HIV has been on the rise for a decade; in sub-Saharan Africa, women constitute 60 percent of people living with disease. ...

New monkey model for AIDS offers promise for medical research

June 19, 2014
HIV-1, the virus responsible for most cases of AIDS, is a very selective virus. It does not readily infect species other than its usual hosts – humans and chimpanzees. While this would qualify as good news for most mammals, ...

Herpes virus infection drives HIV infection among non-injecting drug users in New York

June 28, 2014
HIV and its transmission has long been associated with injecting drug use, where hypodermic syringes are used to administer illicit drugs. Now, a newly reported study by researchers affiliated with New York University's Center ...

Recommended for you

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

Paris spotlight on latest in AIDS science

July 21, 2017
Some 6,000 HIV experts gather in Paris from Sunday to report advances in AIDS science as fading hopes of finding a cure push research into new fields.

Scientists elicit broadly neutralizing antibodies to HIV in calves

July 20, 2017
Scientists supported by the National Institutes of Health have achieved a significant step forward, eliciting broadly neutralizing antibodies (bNAbs) to HIV by immunizing calves. The findings offer insights for HIV vaccine ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.